Docket No.: 2003.784US

Application No. 10/785,369 Response dated December 20, 2007 Reply to Office Action of September 20, 2007

RECEIVED CENTRAL FAX CENTER

P.06

Amendments to the Claims:

DEC 2 0 2007

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Previously Presented) A process for inhibiting and/or delaying carbamylation of a polypeptide in a urea and/or cyanate containing solution, the process comprising a step of adding a carbamylation-inhibiting compound to the solution, wherein said carbamylation-inhibiting compound is glycinamide.
- 2-5. (Cancelled)
- 6. The process of Claim 1, wherein the polypeptide is a ribonuclease.
- 7. (Previously Presented) The process of Claim 6, wherein the ribonuclease is RNase A.
- 8. (Currently Amended) The process of Claim 1, wherein the carbamylation-inhibiting compound is added to the solution in an amount effective to provide about 100% carbamylation protection of the polypeptide for a period of three weeks.
- 9. (Currently Amended) The process of Claim 1, wherein the concentration of the erabamylation carbamylation-inhibiting compound is between 1 mM and 150 mM.
- 10. (Cancelled)
- 11. (Previously Presented) The process of Claim 9, wherein the cyanate in the solution is at a concentration of about 5 mM.
- 12. (Previously Presented) The process of Claim 1, wherein the carbamylation-inhibiting compound has a buffering capacity of about neutral.
- 13-18 (Cancelled)

973 422 7696 P.07

Docket No.: 2003.784US

Application No. 10/785,369 Response dated December 20, 2007 Reply to Office Action of September 20, 2007

- 19. (Currently Amended) The process of Claim 3, wherein A process for inhibiting and/or delaying carbamylation of a polypeptide in a urea and/or cyanate containing solution, the process comprising a step of adding a carbamylation-inhibiting compound to the solution, wherein the carbamylation-inhibiting compound is the a dipeptide is-selected from the group consisting of Glycine-Glycine (Gly-Gly) and Glycine-Histidine (Gly-His).
- 20. (Previously Presented) The process of Claim 19, wherein the dipeptide is Glycine-Glycine (Gly-Gly).
- 21. (Previously Presented) A process for inhibiting and/or delaying carbamylation of a polypeptide in a urea and/or cyanate containing solution, the process comprising a step of adding a carbamylation-inhibiting compound selected from the group consisting of histidine and 4-hydroxyl proline to the solution, wherein the carbamylation-inhibiting compound is added to the solution in an amount effective to provide about 100% carbamylation protection of the polypeptide for a period of three weeks.
- 22. (New) The process of Claim 19, wherein the concentration of the carbamylation-inhibiting compound is between 1 mM and 150 mM.
- 23. (New) The process of Claim 22, wherein the cyanate in the solution is at a concentration of about 5mM.
- 24. (New) The process of Claim 19, wherein the carbamylation-inhibiting compound has a buffering capacity of about neutral.